224 related articles for article (PubMed ID: 38655311)
1. Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases.
Liu J; Wang F; Hong Y; Luo F
Heliyon; 2024 Apr; 10(8):e29266. PubMed ID: 38655311
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
3. Global research hotspots and research trends on idiopathic pulmonary fibrosis: a bibliometric and visualization analysis.
Ma Y; Zhou R; Wu Q
Ann Palliat Med; 2021 Aug; 10(8):9057-9068. PubMed ID: 34455797
[TBL] [Abstract][Full Text] [Related]
4. Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows.
Chianese M; Screm G; Salton F; Confalonieri P; Trotta L; Barbieri M; Ruggero L; Mari M; Reccardini N; Geri P; Hughes M; Lerda S; Confalonieri M; Mondini L; Ruaro B
Pharmaceuticals (Basel); 2024 May; 17(6):. PubMed ID: 38931376
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
6. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
Makino S
Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
[TBL] [Abstract][Full Text] [Related]
7. Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD.
Shumar JN; Chandel A; King CS
J Clin Med; 2021 May; 10(11):. PubMed ID: 34070297
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review.
Amati F; Stainer A; Polelli V; Mantero M; Gramegna A; Blasi F; Aliberti S
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175556
[TBL] [Abstract][Full Text] [Related]
9. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
10. The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting.
Santos G; Fabiano A; Mota PC; Rodrigues I; Carvalho D; Melo N; Novais-Bastos H; Alexandre AT; Moura CS; Guimarães S; Pereira JM; Carvalho A; Morais A
Pulm Pharmacol Ther; 2023 Dec; 83():102261. PubMed ID: 37758002
[TBL] [Abstract][Full Text] [Related]
11. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
[TBL] [Abstract][Full Text] [Related]
12. [Antifibrotic therapy - new approvals for non-IPF interstitial lung diseases].
Markart P; Drakopanagiotakis F; Wygrecka M
Dtsch Med Wochenschr; 2021 Feb; 146(3):181-184. PubMed ID: 33513653
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors for the long-term use of pirfenidone in patients with fibrosing interstitial lung disease.
Katano T; Sekine A; Ikeda S; Yamakawa H; Misumi T; Okabayashi H; Okuda R; Kitamura H; Baba T; Komatsu S; Hagiwara E; Ogura T
Respir Investig; 2021 Jul; 59(4):414-420. PubMed ID: 33618993
[TBL] [Abstract][Full Text] [Related]
14. The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study.
Cameli P; Alonzi V; d'Alessandro M; Bergantini L; Pordon E; Guerrieri M; Refini RM; Sestini P; Bargagli E
Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009520
[TBL] [Abstract][Full Text] [Related]
15. Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications.
Erre GL; Sebastiani M; Manfredi A; Gerratana E; Atzeni F; Passiu G; Mangoni AA
Drugs Context; 2021; 10():. PubMed ID: 33505482
[TBL] [Abstract][Full Text] [Related]
16. Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD).
Copeland CR; Lancaster LH
Front Med (Lausanne); 2021; 8():743977. PubMed ID: 34722582
[TBL] [Abstract][Full Text] [Related]
17. Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease.
Wilfong EM; Aggarwal R
Ther Adv Musculoskelet Dis; 2021; 13():1759720X211060907. PubMed ID: 34917177
[TBL] [Abstract][Full Text] [Related]
18. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Sarr C; Freiwald M
BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
[TBL] [Abstract][Full Text] [Related]
19. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Magnusson MO; Freiwald M
Respir Med; 2021; 180():106369. PubMed ID: 33798871
[TBL] [Abstract][Full Text] [Related]
20. Progressive fibrotic interstitial lung disease.
Pereira CAC; Cordero S; Resende AC
J Bras Pneumol; 2023; 49(5):e20230098. PubMed ID: 37610955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]